Dr. Cyril Erameh held hope in his hands when the first patient in Nigeria's Irrua Specialist Teaching Hospital enrolled in a clinical trial that could transform how doctors treat one of Africa's deadliest viruses. For decades, Lassa fever—a severe hemorrhagic disease that causes internal bleeding and organ failure—has killed about one in five hospitalized patients across West Africa, yet the only standard treatment doctors had was a drug from the 1980s whose actual effectiveness had never been properly tested in a rigorous clinical trial. Now, for the first time, researchers at Germany's Bernhard Nocht Institute for Tropical Medicine have conducted the first randomized controlled trial of an alternative: an antiviral drug called favipiravir that shows genuine promise.
The stakes could hardly be higher. Between 100,000 and 300,000 people in West Africa contract Lassa fever every year, a virus spread through contact with infected rodents that begins with fever and can rapidly spiral into organ failure and uncontrollable bleeding. Yet because the disease is concentrated in regions with limited research infrastructure, it has languished in therapeutic obscurity. "There is an urgent need for new drugs with proven efficacy for Lassa fever," explains Dr. Mirjam Groger, laboratory group leader at the Bernhard Nocht Institute. "Our knowledge of ribavirin is limited and based primarily on older reports from the 1980s. Furthermore, the mechanism of action of ribavirin in Lassa fever is unclear."
The breakthrough came through an unlikely collaboration spanning two decades. Prof. Dr. Stephan Günther, head of virology at the Berlin institute, built partnerships with specialist centers in Nigeria starting around 20 years ago—particularly the Irrua Specialist Teaching Hospital and the Federal Medical Center Owo—creating the infrastructure and trust necessary to conduct modern clinical research on one of the world's most dangerous pathogens. When favipiravir emerged as a candidate—an antiviral originally developed for influenza that has proven safe in trials for COVID-19 and Ebola—the groundwork was already in place.
The SAFARI trial, conducted across these Nigerian centers in partnership with French colleagues, enrolled 41 patients with mild to moderate Lassa fever. Researchers compared favipiravir against the standard ribavirin treatment, carefully measuring safety, tolerability, and the drug's concentration in patients' blood. The results, published in Nature Medicine, are striking: favipiravir proved safe and well tolerated, with no serious unexpected side effects. More importantly, the drug's activity against the Lassa virus showed measurable promise in human patients—moving it from laboratory theory into clinical reality.
"Ongoing investment in diagnostic infrastructure and in therapeutic and clinical research, in building and strengthening the specialist workforce, and in safety measures at the ISTH paved the way for studies of this kind," notes Dr. Cyril Erameh, the Nigerian physician who led enrollment. His words capture something essential: this breakthrough didn't emerge from wealthy laboratories in isolation, but from sustained partnership and infrastructure investment in the regions where Lassa fever actually kills people.
The work ahead remains substantial—larger efficacy trials are needed to confirm that favipiravir actually saves lives compared to standard treatment. But for the first time in decades, Lassa fever patients have a scientifically grounded reason to hope. In a disease where medical options have been static for 40 years, favipiravir represents genuine progress: a drug tested, proven safe, and ready to be studied further as a potential lifesaver.